Contineum Therapeutics (CTNM) closed at $8.81 on November 5, 2026, down 10.0% from the previous close, on volume of 576,447 shares (30-day average 1,113,799).
Data as of November 5, 2026.
TipRanks (Tue, 3-Nov 7:15 PM ET)
Contineum Therapeutics GAAP EPS of -$0.49
Seeking Alpha News (Tue, 3-Nov 5:31 PM ET)
Contineum Therapeutics Reports Third-Quarter 2026 Financial Results
Business Wire (Tue, 3-Nov 4:05 PM ET)
Contineum Therapeutics to Present at the Stifel 2026 Healthcare Conference
Business Wire (Thu, 29-Oct 4:05 PM ET)
Business Wire (Mon, 14-Sep 4:05 PM ET)
Contineum Therapeutics to Present at the 2026 Morgan Stanley Global Healthcare Conference
Business Wire (Tue, 25-Aug 4:05 PM ET)
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.
Contineum Therapeutics trades on the NASDAQ stock market under the symbol CTNM.
As of November 6, 2026, CTNM stock price climbed to $9.39 with 135,297 million shares trading.
CTNM has a beta of 1.11, meaning it tends to be more sensitive to market movements. CTNM has a correlation of 0.02 to the broad based SPY ETF.
CTNM has a market cap of $353.26 million. This is considered a Small Cap stock.
Last quarter Contineum Therapeutics reported $0 in Revenue and -$.49 earnings per share. This fell short of revenue expectation by $-2 million and missed earnings estimates by -$.04.
The top ETF exchange traded funds that CTNM belongs to (by Net Assets): VTI, IWM, VXF, IWN, VTWO.
CTNM has underperformed the market in the last year with a return of -10.1%, while the SPY ETF gained +9.9%. In the last 3 month period, CTNM fell short of the market, returning -38.5%, while SPY returned -4.0%. However, in the most recent 2 weeks CTNM has outperformed the stock market by returning +11.9%, while SPY returned -3.5%.
CTNM support price is $8.26 and resistance is $9.36 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CTNM shares will trade within this expected range on the day.
